• Active, not recruiting

NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial

Updated: Sep 19

GEM-CESAR trial


PETHEMA/GEM

Spanish Myeloma Group

GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group


KRd

Gem Cesar trial myeloma pethema

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma


Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation. Approximately 3 months after peripheral blood stem cell transplantation patients will receive consolidation treatment during 2 months. Subsequently patients will start maintenance treatment during 24 months. Therefore, the total duration of the treatment will be approximately 36 months.


Sponsor

PETHEMA Foundation


Collaborators

Celgene Corporation Amgen

 

ClinicalTrials.gov Identifier: NCT02415413

Official Title: A Phase II Multicenter Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy, Followed by High-dose Therapy With Melphalan and Autologous Peripheral Blood Stem Cell Transplantation, Consolidation With KRd, and Maintenance With Lenalidomide and Dexamethasone in Patients ≤ 70 Years Old With Smoldering Multiple Myeloma (SMM) With High Risk of Progression to Symptomatic Myeloma

First Posted : April 14, 2015

Click here for details on ClinicalTrials.gov

 

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information


Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

 

1829 Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Program: Oral and Poster Abstracts

Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster I

Hematology Disease Topics & Pathways:

Clinical Trials, Workforce, Plasma Cell Disorders, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Diseases, Therapies, Lymphoid Malignancies, Study Population, Clinical Practice (e.g. Guidelines, Health Outcomes and Services, and Survivorship, Value; etc.)

Saturday, December 11, 2021, 5:30 PM-7:30 PM

Click here for details

 

Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS)

2020 ASCO Annual Meeting

Abstracts; 8512

Click here for details

 

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

731.CLINICAL AUTOLOGOUS TRANSPLANTATION: RESULTS| NOVEMBER 13, 2019

Blood (2019) 134 (Supplement_1): 781.

Click here for details

 

Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR) Jan 3, 2018

(33) Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR) - YouTube


How do the two approaches to treating high-risk smoldering multiple myeloma (HRSMM) patients differ? Feb 8, 2018

(33) How do the two approaches to treating high-risk smoldering multiple myeloma (HRSMM) patients differ? - YouTube


Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM) Dec 13, 2019

(33) Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM) - YouTube


Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Pts Included in the GEM-CESAR Trial Dec 16, 2019

(33) Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Pts Included in the GEM-CESAR Trial - YouTube


Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma pts Jun 11, 2020

(33) Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma pts - YouTube

Learn more:

https://www.myeloma.org

https://www.youtube.com/c/IMFMyeloma/videos

 

Location

Spain

 

Spanish Myeloma Group (GEM-PETHEMA) Posts


NCT00480363: Phase 3: Revlimid / Dex ( ReDex) VS Observation in Smoldering MM (QUIREDEX)

Click here for details


NCT00461747: Phase 3 - GEM05 for Patients With Multiple Myeloma Under 65 Years (GEM05MENOS65)

Click here for details


NCT01916252: Phase 3 - Bortezomib, Lenalidomide & IV Busulfan Under 65 - (GEM2012MENOS65) PETHEMA

Click here for details


NCT02406144: Phase 3 - Maint. Lenalidomide, Dex VS Lenalidomide, Dex. & MLN9708 After ASCT NDMM

Click here for details


NCT03336073: Phase 2: GEM-KyCyDex - Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma

Click here for details


NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma

Click here for details


CT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide

Click here for details

Posts Archive